Future_Oncology_Infographic_Wirth_Revised(1).pdf (424.91 kB)

Supplementary figure - LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naıve RET-mutant medullary thyroid cancer

figure

posted on 2022-08-17, 13:54 authored by Lori J Wirth, Marcia S Brose, Rossella Elisei, Jaume Capdevila, Ana O Hoff, Mimi I Hu, Makoto Tahara, Bruce Robinson, Ming Gao, Meng Xia, Patricia Maeda, Eric Sherman

LIBRETTO-531: a phase III study of

selpercatinib in multikinase inhibitor-na¨ıve

RET-mutant medullary thyroid cancer

History

Usage metrics

Keywords

medullary thyroid cancer phase III trial RET alteration RET kinase inhibitor RET mutation selpercatinib targeted therapy

Licence

CC BY-NC-ND 4.0

Supplementary figure - LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naıve RET-mutant medullary thyroid cancer

History

Usage metrics

Categories

Keywords

Licence

Exports